Literature DB >> 19288272

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

Nicholas B P Thomas1, Iain R Hutcheson, Lee Campbell, Julia Gee, Kathryn M Taylor, Robert I Nicholson, Mark Gumbleton.   

Abstract

Caveolin-1 displays both tumour-suppressor and tumour-promoter properties in breast cancer. Using characterised preclinical cell models for the transition of oestrogen-sensitive (WT-MCF-7 cells) to a tamoxifen-resistant (TAM-R cells) phenotype we examined the role caveolin-1 in the development of hormone-resistant breast cancer. The WT-MCF-7 cells showed abundant expression of caveolin-1 which potentiated oestrogen-receptor (ERalpha) signalling and promoted cell growth despite caveolin-1 mediating inhibition of ERK signalling. In TAM-R cells caveolin-1 expression was negligible, repressed by EGF-R/ERK signalling. Pharmacological inhibition of EGFR/ERK in TAM-R cells restored caveolin-1 and also resulted in the emergence of pools of phosphorylated caveolin-1. WT-MCF-7 cells exposed to tamoxifen for upto 12 weeks displayed increased caveolin-1 (peaking by week 2) followed (after week 8) by a marked decrease as the cells progress to develop a stable tamoxifen-resistant phenotype. The targeted down-regulation (siRNA) of caveolin-1 in WT-MCF-7 cells reduced growth but did not affect their sensitivity to tamoxifen, suggesting loss of caveolin-1 alone is not sufficient to confer tamoxifen-resistance. Hyperactivation of EGFR/ERK is a feature of tamoxifen-resistant breast cancer cells, a principal driver of cell growth. Recombinant expression of caveolin-1 in TAM-R cells did not affect EGFR/ERK activity, potentially due to mislocalisation of caveolin-1 through hyperactivation of the mTOR pathway or altered caveolin-1 phosphorylation. This work defines a novel role for caveolin-1 with implications for the clinical course of breast cancer and identifies caveolin-1 as a potential drug target for the treatment of early oestrogen-dependent breast cancers. Further, the loss of caveolin-1 may have benefit as a molecular signature for tamoxifen resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288272     DOI: 10.1007/s10549-009-0355-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells.

Authors:  Ali Vaziri-Gohar; Yan Zheng; Kevin D Houston
Journal:  Mol Cancer Res       Date:  2017-01-17       Impact factor: 5.852

2.  Autophagy in breast cancer and its implications for therapy.

Authors:  Kirti Jain; Krishna S Paranandi; Savitha Sridharan; Alakananda Basu
Journal:  Am J Cancer Res       Date:  2013-06-20       Impact factor: 6.166

3.  Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.

Authors:  Lee Campbell; Ghaith Al-Jayyoussi; Robert Gutteridge; Nigel Gumbleton; Rosie Griffiths; Simon Gumbleton; Mathew W Smith; David F R Griffiths; Mark Gumbleton
Journal:  J Transl Med       Date:  2013-10-11       Impact factor: 5.531

4.  Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.

Authors:  Stephanie K Guest; Ricardo Ribas; Sunil Pancholi; Joanna Nikitorowicz-Buniak; Nikiana Simigdala; Mitch Dowsett; Stephen R Johnston; Lesley-Ann Martin
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

5.  Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.

Authors:  Ran Cheng; Ya-Jing Liu; Jun-Wei Cui; Man Yang; Xiao-Ling Liu; Peng Li; Zhan Wang; Li-Zhang Zhu; Si-Yi Lu; Li Zou; Xiao-Qin Wu; Yu-Xia Li; You Zhou; Zheng-Yu Fang; Wei Wei
Journal:  Oncotarget       Date:  2017-05-02

6.  Identification of intracellular cavin target proteins reveals cavin-PP1alpha interactions regulate apoptosis.

Authors:  Kerrie-Ann McMahon; Yeping Wu; Yann Gambin; Emma Sierecki; Vikas A Tillu; Thomas Hall; Nick Martel; Satomi Okano; Shayli Varasteh Moradi; Jayde E Ruelcke; Charles Ferguson; Alpha S Yap; Kirill Alexandrov; Michelle M Hill; Robert G Parton
Journal:  Nat Commun       Date:  2019-07-22       Impact factor: 14.919

7.  Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM.

Authors:  Xia Cheng; Shirui Tan; Feifei Duan; Qingqing Yuan; Qingrong Li; Gang Deng
Journal:  Breast Cancer       Date:  2019-06-06       Impact factor: 4.239

8.  IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.

Authors:  Yan Zheng; Janel Y Sowers; Kevin D Houston
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-06       Impact factor: 5.555

9.  Co-regulation of cell polarization and migration by caveolar proteins PTRF/Cavin-1 and caveolin-1.

Authors:  Michelle M Hill; Noor Huda Daud; Cho Sanda Aung; Dorothy Loo; Sally Martin; Samantha Murphy; Debra M Black; Rachael Barry; Fiona Simpson; Libin Liu; Paul F Pilch; John F Hancock; Marie-Odile Parat; Robert G Parton
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

10.  CpG island shore methylation regulates caveolin-1 expression in breast cancer.

Authors:  X Rao; J Evans; H Chae; J Pilrose; S Kim; P Yan; R-L Huang; H-C Lai; H Lin; Y Liu; D Miller; J-K Rhee; Y-W Huang; F Gu; J W Gray; Th-M Huang; K P Nephew
Journal:  Oncogene       Date:  2012-11-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.